Ephedrine proposal contains "inadequate" small business impact analysis -- SBA.
This article was originally published in The Tan Sheet
Executive Summary
EPHEDRINE PROPOSED RULE IMPACT ON SMALL BUSINESSES NEEDS FURTHER ANALYSIS via FDA outreach efforts, the Small Business Administration Office of Chief Counsel for Advocacy states in Feb. 3 comments on FDA's proposed regulation of ephedrine alkaloid-containing dietary supplements. "FDA has done an inadequate job of analyzing the impact of the regulation on small entities and in identifying and analyzing less burdensome alternatives," SBA maintains, adding the agency "should develop an outreach strategy to obtain more reliable industry data." The proposal was published in June ("The Tan Sheet" June 9, 1997, pp. 20-23).